Please login to the form below
Incyte
FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
Submission is based on results from the pivotal REACH3 study. The US Food and Drug Administration (FDA) has awarded Incyte’s Jakafi a priority review for the treatment of steroid-refractory ... A decision on the JAK1/2 inhibitor is expected by 22 June
Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
Last week, Eli Lilly and Incyte’s repurposed arthritis treatment baricitinib also scored an EUA in combination with Gilead’s remdesivir for the treatment of hospitalised COVID-19 patients.
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval
Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use
Switzerland: a life sciences hub
American oncology specialist Incyte invested $100m for a monoclonal antibody production site in Yverdon (Vaud).
Incyte launches award programme recognising innovation in GVHD community
have a devastating impact on the lives of patients,” said Barry Flannelly, executive vice president and general manager, US, Incyte. ... Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Senior Account Manager
-
Salary TBC
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
- Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
- Biogen reports new data backing long-term benefit of Spinraza
- G7 expected to donate one billion COVID-19 vaccine doses
- Anna Korving joins Resonant Group as non-executive director
- Resonant Group appoints Stephen Marchant as chief development officer
- Novo Nordisk says Victoza outperforms SGLT2 inhibitors
- Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases
- Nicky Hutchens appointed as deputy managing director at Four Health
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
- Antibiotics: pharma's Cinderella story
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Article:
- The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
- The pursuit of patient diversity in clinical trials
- When all-inclusive isn’t an option, it’s an obligation...
- Overcoming the digital patient recruitment challenges of connecting with patients
- How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...
